NASDAQ$OKUR
OnKure Therapeutics Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ended June 30, 2023 and provided a business update.
Reneo Pharmaceuticals reported a net loss of $19.5 million, or $0.65 per share, for the second quarter of 2023. The company's cash, cash equivalents, and short-term investments totaled $142.7 million as of June 30, 2023. They raised $68.3 million in gross proceeds from a public offering and concurrent private placement of common stock.
- Enrolled over 130 adult patients with PMM due to mtDNA defects into the mavodelpar open-label extension study (STRIDE AHEAD)
- Expanded the inclusion criteria of the STRIDE AHEAD study to allow enrollment of adult patients with PMM due to nuclear DNA (nDNA) defects
- Participated and presented at two major mitochondrial scientific conferences: EUROMIT 2023 Conference (Bologna, Italy) and United Mitochondrial Disease Foundation’s Mitochondrial Medicine Symposium (Charlotte, NC)
- Added to the broad-market Russell 2000® and 3000® Indexes
Headline financials
Revenue & EPS history
Reneo Pharmaceuticals · Revenue · Quarterly
$458K
Forward guidance
The company expects to have sufficient capital to fund operations beyond the potential submission of a new drug application for mavodelpar for the treatment of PMM in the United States anticipated in the first half of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+2.2%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+3.6%
Avg return
30 days after
52%
11 / 21 earnings
Positive
+21.2%
Q2 2025
Best reaction
-10.3%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.7% | -15.0% | -6.3% | |
| Q3 2025 | -5.5% | -2.5% | -3.2% | |
| Q2 2025 | +21.2% | +24.6% | +20.2% | |
| Q1 2025 | +12.5% | +7.5% | +21.0% | |
| Q4 2024 | +3.7% | +4.8% | -40.0% | |
| Q3 2024 | +3.2% | +1.8% | -16.7% | |
| Q2 2024 | +9.7% | +15.7% | +5.2% | |
| Q1 2024 | +2.4% | +3.0% | +0.6% | |
| Q4 2023 | +3.0% | +3.6% | +1.2% | |
| Q3 2023 | -0.9% | +5.6% | +21.1% | |
| Q2 2023 | -6.3% | -15.1% | +7.1% | |
| Q1 2023 | -1.4% | -0.9% | +79.3% | |
| Q4 2022 | -10.3% | -1.0% | +65.1% | |
| Q3 2022 | -3.0% | -8.6% | -35.4% | |
| Q2 2022 | -3.0% | +4.1% | +34.6% | |
| Q1 2022 | -5.9% | -10.8% | -28.2% | |
| Q4 2021 | -1.4% | -6.8% | -34.7% | |
| Q3 2021 | +14.8% | +5.7% | -13.2% | |
| Q2 2021 | +0.1% | -3.2% | +2.0% | |
| Q4 2020 | +7.5% | +2.9% | -2.3% | |
| Q1 2021 | +7.5% | +2.9% | -2.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro